| pubmed-article:18206478 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18206478 | lifeskim:mentions | umls-concept:C0330390 | lld:lifeskim |
| pubmed-article:18206478 | lifeskim:mentions | umls-concept:C0027819 | lld:lifeskim |
| pubmed-article:18206478 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:18206478 | lifeskim:mentions | umls-concept:C0009429 | lld:lifeskim |
| pubmed-article:18206478 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:18206478 | lifeskim:mentions | umls-concept:C0077063 | lld:lifeskim |
| pubmed-article:18206478 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:18206478 | lifeskim:mentions | umls-concept:C0556895 | lld:lifeskim |
| pubmed-article:18206478 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:18206478 | pubmed:dateCreated | 2008-1-21 | lld:pubmed |
| pubmed-article:18206478 | pubmed:abstractText | Trichostatin A (TSA) is a potent histone deacetylase inhibitor and has demonstrated significant antitumor activity against a variety of cancer cell lines. Type I interferons have also shown significant antitumor as well as antiangiogenic activity. In this study, we examined the effectiveness of combination therapy of TSA and interferon beta (IFN-beta) on human neuroblastoma cells in vitro and in vivo using a murine model of retroperitoneal neuroblastoma. | lld:pubmed |
| pubmed-article:18206478 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18206478 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18206478 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18206478 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18206478 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18206478 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18206478 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18206478 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:18206478 | pubmed:issn | 1531-5037 | lld:pubmed |
| pubmed-article:18206478 | pubmed:author | pubmed-author:DavidoffAndre... | lld:pubmed |
| pubmed-article:18206478 | pubmed:author | pubmed-author:SimsThomas... | lld:pubmed |
| pubmed-article:18206478 | pubmed:author | pubmed-author:McGeeMackenzi... | lld:pubmed |
| pubmed-article:18206478 | pubmed:author | pubmed-author:NgCatherine... | lld:pubmed |
| pubmed-article:18206478 | pubmed:author | pubmed-author:DicksonPaxton... | lld:pubmed |
| pubmed-article:18206478 | pubmed:author | pubmed-author:HamnerJohn... | lld:pubmed |
| pubmed-article:18206478 | pubmed:author | pubmed-author:CutshawAaronA | lld:pubmed |
| pubmed-article:18206478 | pubmed:author | pubmed-author:RosatiShannon... | lld:pubmed |
| pubmed-article:18206478 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18206478 | pubmed:volume | 43 | lld:pubmed |
| pubmed-article:18206478 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18206478 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18206478 | pubmed:pagination | 177-82; discussion 182-3 | lld:pubmed |
| pubmed-article:18206478 | pubmed:meshHeading | pubmed-meshheading:18206478... | lld:pubmed |
| pubmed-article:18206478 | pubmed:meshHeading | pubmed-meshheading:18206478... | lld:pubmed |
| pubmed-article:18206478 | pubmed:meshHeading | pubmed-meshheading:18206478... | lld:pubmed |
| pubmed-article:18206478 | pubmed:meshHeading | pubmed-meshheading:18206478... | lld:pubmed |
| pubmed-article:18206478 | pubmed:meshHeading | pubmed-meshheading:18206478... | lld:pubmed |
| pubmed-article:18206478 | pubmed:meshHeading | pubmed-meshheading:18206478... | lld:pubmed |
| pubmed-article:18206478 | pubmed:meshHeading | pubmed-meshheading:18206478... | lld:pubmed |
| pubmed-article:18206478 | pubmed:meshHeading | pubmed-meshheading:18206478... | lld:pubmed |
| pubmed-article:18206478 | pubmed:meshHeading | pubmed-meshheading:18206478... | lld:pubmed |
| pubmed-article:18206478 | pubmed:meshHeading | pubmed-meshheading:18206478... | lld:pubmed |
| pubmed-article:18206478 | pubmed:meshHeading | pubmed-meshheading:18206478... | lld:pubmed |
| pubmed-article:18206478 | pubmed:meshHeading | pubmed-meshheading:18206478... | lld:pubmed |
| pubmed-article:18206478 | pubmed:meshHeading | pubmed-meshheading:18206478... | lld:pubmed |
| pubmed-article:18206478 | pubmed:meshHeading | pubmed-meshheading:18206478... | lld:pubmed |
| pubmed-article:18206478 | pubmed:meshHeading | pubmed-meshheading:18206478... | lld:pubmed |
| pubmed-article:18206478 | pubmed:meshHeading | pubmed-meshheading:18206478... | lld:pubmed |
| pubmed-article:18206478 | pubmed:meshHeading | pubmed-meshheading:18206478... | lld:pubmed |
| pubmed-article:18206478 | pubmed:meshHeading | pubmed-meshheading:18206478... | lld:pubmed |
| pubmed-article:18206478 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18206478 | pubmed:articleTitle | The efficacy of combination therapy using adeno-associated virus--interferon beta and trichostatin A in vitro and in a murine model of neuroblastoma. | lld:pubmed |
| pubmed-article:18206478 | pubmed:affiliation | Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. | lld:pubmed |
| pubmed-article:18206478 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18206478 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:18206478 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:18206478 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
